Figure 1.
Gender and age distribution of the study participants (5-year intervals).
Table 1.
Vaccination and TBE status of the study participants.
Figure 2.
Serum positivity rate (SPR), and geometric mean titer (GMT) in relation to vaccination status.
SPR and GMT in relation to number of vaccine doses (0–5), or previous TBE disease. The “0(ab)” group is individuals who decided not to get vaccinated because they knew they were antibody positive. (A) SPR for Enzygnost, Immunozym and RFFIT, (B) GMT with 95% CI measured using Enzygnost, (C) GMT with 95% CI measured using Immunozym. Both SPR (p<0.001, Fisher’s) and GMT (p<0.001, Dunn’s) was significantly higher after 4 and 5 doses compared to 3 doses, for all three assays.
Figure 3.
Serum positivity rate (SPR), and geometric mean titer (GMT), in relation to age group.
(A, B) SPR for Enzygnost, Immunozym and RFFIT for individuals that have received 3 (A) or 4 (B) vaccine doses. (C, D) GMT with 95% CI measured using Enzygnost for individuals that have received 3 (C) or 4 (D) vaccine doses. (E, F) GMT with 95% CI measured using Immunozym for individuals that have received 3 (E) or 4 (F) vaccine doses. Both SPR (p<0.001, Chi-square test for trend) and GMT (p<0.001, Kruskal-Wallis) decreased significantly with age with all three assays for participants that had received 3 doses. The trend was not significant for participants that had received 4 doses.
Figure 4.
Linear regression of age versus antibody titer.
Grouped by study participants that have received 3 (n = 227), 4 (n = 155) or 5 (n = 34) vaccine doses. Analyzed using: (A) Enzygnost, and (B) Immunozym.
Table 2.
Analysis of 1st (0-month) and 2nd (3-month) serum from 3 study participants (each vaccinated with 3 doses), bitten by TBEV containing ticks.
Figure 5.
Receiver-Operating Characteristic (ROC) curves.
Displaying the tradeoff between the sensitivity (true positive rate) and the 1-specificity (false positive rate), for Enzygnost and Immunozym for different cutoffs, in reference to the neutralizing antibody assay RFFIT as golden standard.
Table 3.
Comparison of antibody analyses results between Enzygnost and Immunozym using the cutoffs defined by each manufacturer.